Stopping Ozempic? New study reveals surprising weight regain results after GLP-1s

With millions of group utilizing injectable GLP-1 medications for illustration Ozempic, Wegovy aliases Zepbound, galore whitethorn wonderment what happens if they stop.

Previous objective tests suggested a discouraging "rebound" effect, wherever patients regained a important portion of their mislaid weight almost instantly aft ending treatment.

However, a caller study from Cleveland Clinic, published successful nan diary Diabetes, Obesity and Metabolism, offers a much hopeful position connected what happens erstwhile nan injections stop.

SPECIFIC AMOUNT OF NIGHTLY SLEEP MAY LOWER DIABETES RISK, RESEARCHERS FIND

The study looked astatine astir 8,000 adults successful Ohio and Florida who utilized semaglutide aliases tirzepatide for 3 to 12 months earlier stopping, according to a property release.

Unlike tightly controlled objective trials, nan researchers looked astatine "real-world" outcomes wherever patients often move from 1 medicine to another.

Patients only regained a mini information of nan wide weight they mislaid successful nan caller study. (iStock)

Overall, patients did not acquisition important weight regain successful nan twelvemonth aft stopping a GLP-1. Among those treated specifically for obesity, nan mean weight nonaccomplishment earlier stopping was 8.4%; 1 twelvemonth later, they had regained conscionable 0.5% connected average.

"Our real-world information show that galore patients who extremity semaglutide aliases tirzepatide restart nan medicine aliases modulation to different obesity treatment, which whitethorn explicate why they regain little weight than patients successful randomized trials," said lead study writer Dr. Hamlet Gasoyan successful nan property release.

NEW WEGOVY PILL OFFERS NEEDLE-FREE WEIGHT LOSS — BUT MAY NOT WORK FOR EVERYONE

This suggests that nan rebound seen successful objective tests whitethorn beryllium a consequence of patients being near without replacement support, a script that doesn't person to hap successful objective practice, researchers say.

An estimated 27% of patients transitioned to different medications, including older-generation obesity drugs, while different 20% yet restarted their original medicine erstwhile security issues aliases broadside effects were resolved.

An estimated 27% of patients transitioned to different medications. (iStock)

Another 14% transitioned to intensive manner modification programs, moving intimately pinch dietitians and workout specialists.

CLICK HERE FOR MORE HEALTH STORIES

Patients who maintained their weight tended to stay engaged pinch nan healthcare system, whether done replacement prescriptions aliases system manner support, nan researchers noted.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

There were immoderate limitations to nan study.

"We included big patients from a azygous ample integrated wellness strategy successful Ohio and Florida," nan authors noted. "Patient characteristics and healthcare transportation patterns alteration crossed nan U.S., which whitethorn limit nan generalizability of our findings."

Some of nan observed weight simplification whitethorn beryllium associated pinch different interventions that nan squad was incapable to capture. (iStock)

Some of nan observed weight simplification whitethorn beryllium associated pinch other interventions that nan researchers were incapable to capture.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

"In our early work, we will analyse nan comparative effectiveness of replacement curen options for obesity successful patients who discontinue semaglutide aliases tirzepatide, to thief patients and their clinicians make informed decisions," Gasoyan added.